Outcomes of thromboprophylaxis with enoxaparin vs. unfractionated heparin in medical inpatients by McGarry, Lisa J et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Thrombosis Journal
Open Access Original clinical investigation
Outcomes of thromboprophylaxis with enoxaparin vs. 
unfractionated heparin in medical inpatients
Lisa J McGarry1, Michael E Stokes2 and David Thompson*3
Address: 1Health Economics & Outcomes Research, i3 Innovus, 10 Cabot Rd., Suite 304, Medford, MA 02155-5173, USA, 2Center for Health 
Economics & Policy, United BioSource Corporation, 101 Station Landing, Medford, MA 02155, USA and 3Global Health Economics, i3 Innovus, 
10 Cabot Rd., Suite 304, Medford, MA 02155-5173, USA
Email: Lisa J McGarry - lmcarry@innovus.com; Michael E Stokes - me_stokes@yahoo.com; David Thompson* - dthompson@innovus.com
* Corresponding author    
Abstract
Background: Clinical trials have shown low-molecular weight heparin (LMWH) to be at least as
safe and efficacious as unfractionated heparin (UFH) for preventing venous thromboembolism
(VTE) in acutely-ill medical inpatients.
Objective: To compare clinical and economic outcomes among acutely-ill medical inpatients
receiving the LMWH enoxaparin versus UFH prophylaxis in clinical practice.
Methods:  Using a large, multi-hospital, US database, we identified persons aged ≥40 years
hospitalized for ≥6 days for an acute medical condition (including circulatory disorders, respiratory
disorders, infectious diseases, or neoplasms) from Q4 1999 to Q1 2002. From these patients, those
who received thromboprophylaxis with either enoxaparin or UFH were identified. Surgical patients
and those requiring or ineligible for anticoagulation were excluded. We compared the incidence of
deep-vein thrombosis (DVT), pulmonary embolism (PE), and all VTE (i.e., DVT and/or PE).
Secondary outcomes were occurrence of side-effects, length of hospital stay and total costs.
RESULTS: 479 patients received enoxaparin prophylaxis and 2,837 received UFH. The incidence of
VTE was 1.7% with enoxaparin prophylaxis versus 6.3% with UFH (RR = 0.26; p < 0.001).
Occurrence of side effects, length of stay (10.00 days with enoxaparin vs. 10.26 days with UFH; p
= 0.348) and total costs ($18,777 vs. $17,602; p = 0.463) were similar in the 2 groups.
Conclusion:  We observed a 74% lower risk of VTE among patients receiving enoxaparin
prophylaxis versus UFH prophylaxis. There was no significant difference in side effects or economic
outcomes. These results provide evidence that the LMWH enoxaparin is more effective than UFH
in reducing the risk of VTE in current clinical practice.
Background
Acutely-ill medical inpatients – such as those hospitalized
for congestive heart failure (CHF), chronic obstructive
pulmonary disease (COPD), acute infections, or cancer –
often have prolonged hospital stays with periods of
immobility that place them at increased risk of venous
thromboembolism (VTE) [1]. Because these patients fre-
quently have additional risk factors (e.g., history of VTE,
advanced age, obesity, varicose veins, estrogen use), the
potential benefits of thromboprophylaxis in this popula-
tion are substantial [1]. The two most commonly-used
methods of thromboprophylaxis in acutely-ill medical
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patients are low-molecular weight heparin (LMWH) and
unfractionated heparin (UFH) [2]. Clinical trials con-
ducted among medical inpatients have shown thrombo-
prophylaxis with LMWH to be at least as safe and
efficacious as UFH in this population, and LMWH may
offer clinical advantages over UFH, including longer dura-
tion of action, more predictable response, and once-daily
subcutaneous administration [3-7]. However, the out-
comes of using these prophylaxis methods in the real-
world clinical setting have not been examined. The pur-
pose of this study was to compare the clinical and eco-
nomic benefit of these two methods of
thromboprophylaxis using data from real-world clinical
practice. The study time period was from the Q4 1999
through the Q1 2002. The study focuses on the LMWH
enoxaparin, which is the most widely used LMWH in the
US and the most frequently studied in this indication.
Methods
Data source
Data are from the Cerner HealthFacts Database, a data
warehouse containing hospital records for approximately
2.8 million patients from acute-care institutions through-
out the U.S. Patient records include principal and second-
ary diagnoses (in ICD-9-CM format); inpatient
procedures (in ICD-9-CM format) and procedure date;
and drugs dispensed (in National Drug Code format)
with dispensing date, dosage, and frequency of adminis-
tration. Patient demographic information (age, sex, race)
and descriptive hospital information (geographic region,
number of beds, teaching vs. nonteaching) are provided.
Dates of admission and discharge, discharge status, and
total billed charges are reported for each inpatient stay.
Patient records in this database have been de-identified in
compliance with the Health Insurance Portability and
Accountability Act of 1996 (HIPAA) Privacy Rule, and
records relating to a common hospital discharge are
linked using a non-personal identifier assigned by the
data vendor [8]. The dataset obtained for this study
encompassed Q4 1999 through the Q1 2002.
Sample selection
To select patients at high risk of thromboembolism, the
dataset included only those aged ≥ 40 years at admission
with an inpatient stay ≥ 6 days. We focused on patients
with serious medical conditions by excluding patients
undergoing surgery (see additional file 1) within two days
of admission. We then classified patients based on the
ICD-9-CM code (inclusive of all 4th & 5th digit classifica-
tions) recorded as their principal diagnosis and selected
only those patients with principal diagnoses of: (1) respi-
ratory disorders (ICD-9-CM 460–519, 748, 786, 996.84,
997.3); (2)circulatory disorders (390–398, 410–459,
997.1, 997.2); (3)infectious diseases (001–139, 680–686,
730, 996.6, 997.62, 998.3, 998.5, 999.3); and (4)neo-
plasms (140–239). We excluded as medically ineligible
for thromboprophylaxis, patients with a diagnosis of
active peptic ulcer (ICD-9-CM 530.2, 531.0–531.3,
532.0–532.3, 533.0–533.3, 534.0–534.3), malignant
hypertension, including renal disease with or without
renal failure (401.0, 402.0, 403.0, 404.0, 405.0), blood
diseases (280–289), or HIV infection (V08, 042, 079.53),
as well as those undergoing intubation of the gastrointes-
tinal or respiratory tracts (96.0) within the first two days
of admission. Pregnant women were excluded based on a
diagnosis of pregnancy (630–677) or evidence of obstet-
rical procedures (72–75). The specific disorders corre-
sponding to each ICD-9-CM code for inclusion and
exclusion criteria are listed in additional file 1.
We selected patients receiving prophylaxis with enoxa-
parin or UFH by calculating the daily dosage of anticoag-
ulants dispensed within the first two days of admission.
Patients receiving an enoxaparin dosage of 30–60 mg/day
were deemed to be receiving enoxaparin thromboprophy-
laxis and those receiving a UFH dosage between 5,000 and
15,000 IU/day to be receiving UFH thromboprophylaxis.
Those who received any combination of enoxaparin and
IV UFH, or received another anticoagulant in addition to
enoxaparin or UFH (including dalteparin, tinzaparin,
ardeparin, nadroparin, or warfarin), during the first two
days of admission were excluded from the analysis. In
addition, patients who received high-dose enoxaparin
(>100 mg/day) or UFH (>25,000 IU/day) within two days
of admission were assumed to be receiving treatment for
VTE or other conditions present at admission, and were
excluded. Because enoxaparin dosages of >60 to <100 mg/
day and UFH dosages of >15,000-<25,000 IU/day could
not be classified definitively as prophylaxis vs. treatment,
patients receiving dosages in these ranges within two days
of admission also were excluded. Patients were allowed to
receive up to 48 hours of low-dose therapy with a second
anticoagulant at any point after their first two days in hos-
pital; those receiving >48 hours were excluded unless this
therapy was subsequent to a diagnosis of VTE. Because
patients may receive anticoagulant treatment for non-
thrombotic disorders, we excluded those who received
high-dose anticoagulant at any point during their hospital
stay and had a diagnosis of myocardial infarction (ICD-9-
CM 410), cardiac dysrhythmia (427), angina (413), or
valve disorders (394–397, 424). Finally, to ensure that we
had a complete record for each hospitalization, we
excluded patients missing discharge diagnoses and/or
billed charges, and those transferred from or discharged to
another acute-care facility. Sample selection and exclusion
criteria were specified a priori, except those related to drug
dosing, which were finalized after examination of the
data.Thrombosis Journal 2006, 4:17 http://www.thrombosisjournal.com/content/4/1/17
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Study measures
The primary outcome measure was the occurrence of VTE
(deep-vein thrombosis [DVT] and/or pulmonary embo-
lism [PE]) during the hospitalization. A diagnosis of DVT
was identified by either: (1) an ICD-9-CM diagnosis of
451–453 (inclusive of all 4th and 5th digit classifications);
or (2) receipt of a therapeutic dosage of either enoxaparin
(i.e., >100 mg/day) or heparin (>25,000 IU/day) at any
time after the first two inpatient days. A diagnosis of PE
was identified by ICD-9-CM code 415.1. Secondary out-
come measures were the occurrence of major bleeds (ICD-
9-CM 286.5, 430–432, 459.0, 578, 786.3) and thrombo-
cytopenia (287.4–287.5), as well as death in hospital,
length of hospital stay, and estimated inpatient costs. Spe-
cific diagnoses corresponding to each ICD-9-CM code are
detailed in additional file 1. Because the ICD-9-CM diag-
nosis codes used to identify bleeding and thrombocytope-
nia are not associated with a date of diagnosis, we were
not able to determine if these outcomes occurred after
receipt of the study drug, therefore all occurrences of these
outcomes were considered. Similarly, because the cause of
death was not available, all deaths in hospital were con-
sidered.
Data analysis
Descriptive characteristics of the sample were examined
and risk factors for VTE identified by ICD-9-CM diagnosis
code, including CHF (428.0), COPD (490–492, 496),
fracture of pelvis, femur or tibia (808, 820–821), inflam-
matory bowel disease (558.9), and nephrotic syndrome
(581). Drug records were inspected to identify patients
receiving oral estrogen. Dosing for each method of proph-
ylaxis also was noted. Costs of hospitalization were esti-
mated from billed charges using cost-to-charge ratios
from the Centers for Medicare & Medicaid Services (CMS)
Prospective Payment System (PPS) [9]. Because informa-
tion necessary to link the discharging institutions to their
corresponding CMS records was not available, we
matched records to average cost-to-charge ratios by
region, hospital size (i.e., bed count category), and teach-
ing versus non-teaching status, and used these ratios to
estimate costs. Categorical outcomes were compared
between patients receiving prophylaxis with enoxaparin
versus UFH using risk-ratios and two-sided Χ2 statistics, or
the Fischer's exact test where expected cell frequencies
were <5; differences in continuous measures were com-
pared using Student's t-test.
Patients in the database were not randomly assigned to
prophylaxis; therefore we used the propensity score
method to control for confounding [10]. To assign a pro-
pensity score to each patient, a logistic regression model
predicting receipt of enoxaparin prophylaxis as a binary
outcome from patient and hospital characteristics was
estimated from the data. The propensity scores range
between zero and one, representing each patient's pre-
dicted probability of receiving enoxaparin (versus UFH)
prophylaxis conditional on his or her baseline covariates.
Various predictive models were evaluated by comparing
the difference in -2 log likelihoods to a Χ2 distribution
with the appropriate degrees of freedom and rejecting
non-significant covariates at α = 0.10.
The propensity score generated for each patient from the
final model was used to perform a matched analysis in
which patients were divided into five strata (i.e., quintiles)
based on the propensity score distribution in the overall
sample. For categorical measures, stratum-specific risk
ratios were calculated among the patients in each quintile.
These risk ratios were combined using the Mantel-Haen-
szel method, and compared using the Mantel-Haenszel Χ2
test; homogeneity of risk-ratios across the strata was eval-
uated using the Breslow-Day test. For continuous meas-
ures, means calculated within each quintile were averaged
across the quintiles and differences between treatment
groups compared using the F-statistic. Homogeneity was
tested using an interaction term for prophylaxis group and
stratum.
Stratified analyses by dose and duration of prophylaxis
were conducted to examine the effect of treatment regi-
men on outcomes. Lastly, sensitivity analyses were per-
formed to examine the effect of possible misclassification
of patients by drug exposure or outcome on our findings.
Except where noted, results were considered to be statisti-
cally significant at α = 0.05.
Results
Patient characteristics
We identified 479 acutely-ill medical inpatients receiving
enoxaparin prophylaxis and 2,837 receiving UFH proph-
ylaxis who conformed to study inclusion and exclusion
criteria [Figure 1]. The median daily dose of enoxaparin
received by the enoxaparin prophylaxis cohort was 60 mg/
day. Sixty-one percent of enoxaparin patients received this
dose, 36% received 40 mg/day and the remainder received
either 30 or 50 mg/day. The median daily dose of UFH,
received by 78% of patients in the UFH prophylaxis
cohort, was 10,000 IU/day; 14% received a lower and 8%
a higher dose.
Enoxaparin patients were older than UFH patients and
were more likely to be female and white (Table 1). The
distribution of diagnoses in the two groups was roughly
the same; however, patients with circulatory disorders
comprised a larger proportion of the patients in the UFH
cohort, while those with acute infections were a larger
proportion of the enoxaparin patients. Risk factors for
VTE were similar in the two groups, with the exception of
CHF and fractures of the lower limb, which were signifi-Thrombosis Journal 2006, 4:17 http://www.thrombosisjournal.com/content/4/1/17
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cantly more common among enoxaparin patients than
UFH patients. The patient sample was weighted toward
the northeastern region, and enoxaparin prophylaxis
patients were more likely to have been admitted to a hos-
pital in the northeast and to moderate-sized, non-teach-
ing hospitals than UFH patients.
Outcomes and costs
The overall incidence of DVT among study subjects was
5.2%, and the incidence of all VTE (DVT and/or PE) was
5.7%. The risks of PE (p = 0.010), and all VTE (p < 0.001)
over the course of hospitalization were significantly lower
in the group receiving enoxaparin prophylaxis than
Patients included in the analysis and reason for exclusion Figure 1
Patients included in the analysis and reason for exclusion.
aNo surgical procedure w ithin first 2 days of admission
bPrimary diagnosis of circulatory, respiratory, infectious, or neoplasmic disease
cProphylaxis dose of 30-60 mg/day for enoxaparin and 5,000-15,000 IU/day for UFH within first 2 days of admission
dNo high dose enoxaparin (>= 100 mg / day) or UFH (>=25,000 IU/day) w ithin first 2 days of admission
eNo intubation of gastrointestinal or respiratory tract w ithin first 2 days of admission
fPregnancy, HIV, blood disorders, ulcer, malignant hypertension
gNo low -dose anticoagulant other than prophylaxis for > 2 days unless follow ing VTE diagnosis
hAcute myocardial infarction, cardiac dysrhythmia, angina, valve disorders
7,907 received onlyenoxaparin or UFH
prophylaxis
479 had complete records
675 with no excluding
diagnoses
f
586 with no alternative
indications for treatment
h
609 received no low-dose
UFH or other anticoagulant
during followup
g
488 not transferred from/to
acute facility
856 not admitted with VTE
d
3,934 with no alternative
indications for treatment
h
4,372 received no low-
dose enoxaparin or other
anti- coagulant during
followup
g
2,837 had complete
records
51,529 medical patients admitted
between October 1, 1999 and March 31,
2002
a
31,780 admitted with selected
diagnoses
b
10,092 received UFH or enoxaparin
prophylaxis
c
3,317 not transferred
from/to acute facility
4,805 with no excluding
diagnoses
f
1,083 enoxaparin patients 6,824 UFH patients
819 not intubated
e 5,949 not intubated
e
6,307 not admitted with
VTE
dThrombosis Journal 2006, 4:17 http://www.thrombosisjournal.com/content/4/1/17
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among those receiving UFH prophylaxis (Table 2). There
was no significant difference in the risks of major bleeds
(p = 0.966) and death in hospital (p = 0.843) between
enoxaparin versus UFH patients, and no thrombocytope-
nia was recorded among the patients in either group. Sim-
ilarly, there was little difference in hospital length of stay
(p = 0.348) and costs of hospitalization (p = 0.463)
between patients receiving enoxaparin versus UFH proph-
ylaxis (Table 3).
Propensity score analysis
The variables chosen as important independent predictors
of receipt of enoxaparin versus UFH were sex, race (white
vs. nonwhite), age group (in 10-year increments), diagno-
sis group, presence of CHF, interaction of CHF and diag-
nosis group, fracture of lower limb, hospital region,
hospital size (bed count category) and teaching status.
Covariates were, in general, balanced within the strata.
The adjusted relative risks of DVT (0.25; 95% CI: 0.12,
0.51) and VTE (0.24; 95% CI: 0.12, 0.50) for patients
receiving enoxaparin versus UFH prophylaxis were similar
to, and somewhat more favorable for enoxaparin, than
the unadjusted estimates. The adjusted estimates of the
relative risks of major bleed (1.56; 95% CI 0.83, 2.91) and
death (0.85; 95% CI 0.55, 1.31), while further from the
null than the unadjusted estimates, indicate no significant
difference between patients receiving enoxaparin versus
UFH prophylaxis. We similarly found no significant dif-
ference between the two groups with regard to length of
Table 1: Characteristics of medical inpatients receiving enoxaparin versus UFH prophylaxis
Prophylaxis Received
Characteristic Enoxaparin UFH p-value
N 479 2,837
Age (Mean [Range]) 75.6 (40–98) 71.8 (40–101) <0.001
Age group [n (%)]:
40–49 years 30 (6.3) 185 (6.5) <0.001
50–59 years 39 (8.1) 414 (14.6)
60–69 years 67 (14) 527 (18.6)
70–79 years 131 (27.3) 850 (30.0)
80–89 years 165 (34.4) 687 (24.2)
90+ years 47 (9.8) 174 (6.1)
Female [n (%)] 285 (59.5) 1,506 (53.1) 0.009
White [n (%)] 449 (93.7) 2,302 (81.1) <0.001
Principal diagnosis [n (%)]:
Circulatory 215 (44.9) 1,349 (47.6) 0.062
Respiratory 150 (31.3) 926 (32.6)
Acute Infection 70 (14.6) 296 (10.4)
Neoplasm 44 (9.2) 266 (9.4)
Risk factors for VTE [n (%)]:
CHF 194 (40.5) 810 (28.6) <0.001
COPD 156 (32.6) 826 (29.1) 0.126
Receipt of HRT 19 (4.0) 127 (4.5) 0.615
Obesity (coded as medical 
condition)
21 (4.4) 123 (4.3) 0.962
Inflammatory bowel disease 3 (0.6) 6 (0.2) 0.129
Fracture of lower limb 3 (0.6) 3 (0.1) 0.043
Nephrotic syndrome 1 (0.2) 5 (0.2) 1.000
Geographic region of hospital [n 
(%)]:
Northeast 374 (78.1) 1,227 (43.2) <0.001
Midwest 21 (4.4) 681 (24.0)
South 79 (16.5) 916 (32.3)
West 5 (1.0) 13 (0.5)
Hospital size [n (%)]:
< 200 beds 30 (6.3) 214 (7.5) <0.001
200–499 beds 273 (57.0) 864 (30.5)
500+ beds 176 (36.7) 1,759 (62.0)
Teaching hospital [n (%)] 260 (54.3) 2,235 (78.8) <0.001
VTE = venous thromboembolism, CHF = congestive heart failure, COPD = chronic obstructive pulmonary disease, HRT = hormone replacement 
therapyThrombosis Journal 2006, 4:17 http://www.thrombosisjournal.com/content/4/1/17
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inpatient stay (-0.21; 95% CI -0.99, 0.58) and total costs
($1,249; 95% CI -2,510, 5,008).
Stratified analyses
To explore the effect of dosing of prophylaxis on occur-
rence of VTE, we classified patients receiving enoxaparin
into two groups: those receiving a dosage of 30–40 mg
and those receiving 50–60 mg, and classified patients
receiving UFH into three groups: those receiving 5,000-
<10,000 IU, those receiving 10,000 IU, and those receiv-
ing >10,000–15,000 IU and examined outcomes in these
groups. Using the F-test for trend, we found that the risk
of VTE decreased significantly for UFH patients as the dos-
age of UFH increased, but observed a significant increase
in the risk of VTE among enoxaparin patients at higher
dosages (Table 4).
To examine the effect of duration of prophylaxis on out-
come, we next stratified patients in both treatment groups
into 4 groups: those receiving 1–2 days of prophylaxis; 3–
4 days; 5–6 days and > 6 days. Because we required
patients in our study sample to have been hospitalized for
a minimum of 6 days, all patients had the opportunity to
receive up to 6 days of prophylaxis. Patients receiving with
UFH tended to have fewer days of prophylaxis than those
receiving enoxaparin. In both groups, the risk of VTE
decreased significantly with increased duration of proph-
ylaxis (Table 4).
Sensitivity analyses
To examine the importance of using drug records to iden-
tify patients with VTE, we reanalyzed the data entirely dis-
regarding drug treatment as a marker for VTE and
classifying only those patients with a recorded ICD-9-CM
diagnosis code for DVT or PE as having VTE. The risk-ratio
for VTE for patients receiving enoxaparin versus UFH
prophylaxis using this narrower definition was 0.36 (p =
0.021). Next we explored the effect of possible misclassi-
fication of patients by receipt of enoxaparin and UFH
prophylaxis, by restricting patients to only those receiving
the recommended prophylaxis dosage of 40 mg/day of
enoxaparin (n = 173) or 15,000 IU/day UFH (n = 211). In
this subgroup, there were no cases of VTE among those
receiving enoxaparin prophylaxis versus a risk of 3.3% for
those receiving UFH prophylaxis (p = 0.018).
Discussion
Our comparison of enoxaparin versus UFH in real-world
clinical practice yielded results more favorable for enoxa-
parin than those from clinical trials, which have con-
cluded equivalence between these two prophylaxis
methods [3-7]. This difference in outcome may be
explained in part by differences in the drug dosing used in
the trials versus those we observed in clinical practice. The
two trials in which enoxaparin was nominally (but not
significantly) less efficacious than UFH administered dos-
ages of 20 and 36 mg/day of enoxaparin and 15,000 IU/
Table 2: Incidence of venous thromboembolism and adverse events among medical inpatients receiving enoxaparin versus UFH 
prophylaxis
Prophylaxis Received [N(%)]
Outcome Enoxaparin (N = 479) UFH (N = 2,837) RR (95% CI)
DVT 8 (1.7) 163 (5.8) 0.29 (0.14, 0.59)
PE 0 (0.0) 32 (1.1) 0
VTE (DVT and/or PE) 8 (1.7) 180 (6.3) 0.26 (0.13,0.53)
Adverse Events:
HIT 0 (0.0) 0 (0.0) --
Major Bleed 12 (2.5) 72 (2.5) 0.99 (0.54,1.80)
Death 25 (5.2) 142 (5.0) 1.04 (0.69, 1.58)
DVT = deep-vein thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism; HIT = heparin-induced thrombocytopenia
Table 3: Length of stay in hospital and estimated costs among medical inpatients receiving enoxaparin versus UFH prophylaxis
Prophylaxis Received
Outcome (Mean) Enoxaparin UFH Difference (95% CI)
Length of hospital stay (days) 10.00 10.26 -0.26 (-0.99, 0.46)
Total costs $18,777 $17,602 $1,174 (-2,365, 4,714)Thrombosis Journal 2006, 4:17 http://www.thrombosisjournal.com/content/4/1/17
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day of UFH, in contrast to the median dosages of 60 mg/
day and 10,000 IU/day, that we observed in practice [4,5].
Two other trials that found enoxaparin to be more effica-
cious (but not significantly) than UFH, used dosages of 40
mg/day for enoxaparin and 15,000 IU/day for UFH,
which are consistent with current recommendations
[1,6,7]. The reasons for the use of higher-than-recom-
mended dosages of enoxaparin and lower-than-recom-
mended dosages of UFH that we observed in real-world
practice are unknown, but may reflect differences in ease
of administration and monitoring, as well as perceptions
about the relative safety of the two prophylaxis methods.
When we stratified patients by dosage of anticoagulant
received we found a significant (p < 0.05) trend of fewer
VTEs with higher dosing among UFH patients, but the
opposite trend among enoxaparin patients. The reason for
this seemingly contradictory finding is unclear and may
suggest that some of the patients receiving higher dosages
of enoxaparin were receiving treatment rather than proph-
ylaxis for VTE. This is consistent with our finding that the
90 patients receiving a dosage of UFH >15,000 IU to
20,00 IU not included in our analysis had a higher rate of
VTE (12%) than the patients receiving dosages between
5,000–15,000 IU included in the study. In any case, the
results of the stratified analyses suggest that some cases of
VTE among UFH patients may be related to inadequate
UFH dosing. However in sensitivity analyses that com-
pared patients receiving the recommended dosages of 40
mg/day of enoxaparin and 15,000 IU/day of UFH, the
occurrence of VTE among enoxaparin patients remained
significantly lower than that among UFH patients.
We similarly stratified patients by duration of prophylaxis
and found a significant trend of fewer VTEs with longer
duration of thromboprophylaxis. Because patients receiv-
ing UFH prophylaxis tended to have fewer days of proph-
ylaxis than those receiving enoxaparin, some cases of VTE
among UFH patients may be related to shorter duration or
prophylaxis. We note, however, that the occurrence of VTE
was lower among enoxaparin versus UFH patients at all
levels of treatment duration.
Despite the significantly lower overall risk of VTE among
enoxaparin versus UFH patients, we observed no eco-
nomic benefit of thromboprophylaxis with enoxaparin
versus UFH in terms of reduction in either length of hos-
pital stay or total inpatient costs. When pooled across the
two treatment groups, patients with VTE did have signifi-
cantly longer inpatient stays than those without (14.8
days vs. 9.9 days; p = 0.001) and correspondingly higher
inpatient costs ($26,605 vs. $17,241; p = 0.003); how-
Table 4: Incidence of venous thromboembolism among medical inpatients receiving enoxaparin versus UFH prophylaxis by dosage and 
duration of prophylaxis received
Outcome (N [%])
Prophylaxis Received/
Dosage or Days
N % of Patients DVT PE VTE (DVT and/or PE)
Dosage:
Enoxaparin
30–40 mg 186 38.8% 0 (0.0) 0 (0.0) 0 (0.0)
50–60 mg 293 61.2% 8 (2.7) 0 (0.0) 8 (2.7)
UFH
5,000-<10,000 
IU
414 14.5% 47 (11.4) 8 (1.93) 52 (12.6)
10,000 IU 2,221 78.0% 109 (4.9) 23 (1.04) 121 (5.4)
>10,000–15,000 
IU
214 7.5% 7 (3.3) 1 (0.5) 7 (3.3)
Prophylaxis days:
Enoxaparin
1–2 days 74 15.4% 4 (5.4) 0 (0.0) 4 (5.4)
3–4 days 36 7.5% 2 (5.6) 0 (0.0) 2 (5.6)
5–6 days 123 25.7% 2 (1.6) 0 (0.0) 2 (1.6)
> 6 days 246 51.4% 0 (0.0) 0 (0.0) 0 (0.0)
UFH
1–2 days 831 29.3% 109 (13.1) 22 (2.7) 120 (14.4)
3–4 days 227 8.0% 21 (9.25) 2 (0.9) 23 (10.1)
5–6 days 608 21.4% 15 (2.5) 4 (0.7) 15 (2.5)
> 6 days 1,171 41.3% 18 (1.5) 4 (0.3) 22 (1.9)
Bold indicates p for trend <0.05Thrombosis Journal 2006, 4:17 http://www.thrombosisjournal.com/content/4/1/17
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ever, these differences did not translate into overall lower
costs for enoxaparin patients. This lack of apparent eco-
nomic benefit for enoxaparin prophylaxis versus UFH
prophylaxis may be due to the relatively small number of
patients experiencing VTE, our inability to isolate costs
directly related to VTE from the total costs of hospitaliza-
tion, and the high degree of variability in both length of
stay (ranging from 6 to 54 days) and inpatient costs (from
$3,000 to $384,000) among the patients in this sample.
Our study is subject to the limitations inherent in the use
of retrospective administrative data. First, we identified
and classified study subjects based on drug records and
ICD-9-CM coding of diagnoses and procedures taken
from the inpatient record. If these records were inaccurate
or incomplete, subjects may have been misidentified as
eligible, or misclassified by diagnosis or receipt of proph-
ylaxis. Similarly, the incidence of VTE was derived from
information recorded by the treating institutions; there-
fore, the validity of our findings depends on the accuracy
of their record keeping and on our interpretation of the
data. Drug records were used both to classify patients
receiving prophylaxis, and to identify patients experienc-
ing VTE, and assumptions regarding treatment patterns
and dosing were necessary. Sensitivity analyses demon-
strated, however, that our results were not highly depend-
ent on these assumptions, and our conclusions were
similar when we used narrower definitions of prophylaxis
and treatment.
We further note that because VTE was identified from
administrative records, it was not possible to distinguish
between symptomatic and asymptomatic VTEs. Attempts
to identify patients receiving diagnostic testing for VTE
suggested low levels of reporting for these tests, and avail-
able data did not allow us to determine the outcome of
the test except as inferred from treatment received. In
addition, because of the limited information available for
the bleeds identified from ICD-9 diagnostic coding, we
cannot be certain that these outcomes were caused by
administration of either study drug.
Because patients were not randomly assigned to enoxa-
parin versus UFH prophylaxis, underlying differences in
the two groups may have influenced both the selection of
thromboprophylaxis and the occurrence of VTE. We note,
however, that for our results to have been produced solely
by "confounding by indication", treating physicians
would have to systematically administer enoxaparin
prophylaxis to patients at lower risk of VTE than those
receiving UFH prophylaxis. In fact, the enoxaparin
patients in our sample had nominally higher frequencies
of nearly every risk factor for VTE examined. Moreover,
using propensity score techniques to control for con-
founding, we found that enoxaparin patients had lower
risks of VTE than UFH patients across all strata. Neverthe-
less, the extent of uncontrolled confounding in this study
remains unknown.
Finally, in selecting patients for this study, we excluded
groups such as patients aged <40 years, pregnant women,
and patients with certain comorbid conditions; therefore,
extrapolation of our finding to these populations may not
be appropriate.
Summary
Using hospital administrative data, we observed a 74%
lower risk of VTE among acutely-ill medical inpatients
receiving enoxaparin prophylaxis versus UFH prophy-
laxis, but found no difference in occurrence of side-effects,
death in hospital, length of hospital stay, or inpatient
costs. We conclude that enoxaparin is more effective than
UFH in reducing the risk of VTE in acutely-ill medical
patients in current clinical practice.
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